Related Experiment Videos
Hepatitis C: basic and clinical studies
1Second Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Japan.
Insights
Hepatitis C virus (HCV) causes most transfusion-associated and community-acquired hepatitis in Japan. Preventing HCV infection through blood screening is crucial to reduce post-transfusion hepatitis incidence.
Area of Science:
- Hepatology
- Virology
- Epidemiology
Background:
- Hepatitis C virus (HCV), a flavivirus, is linked to transfusion-associated and community-acquired non-A, non-B hepatitis in Japan.
- HCV is prevalent in 2% of blood donors and common in high-risk groups like hemophiliacs and hemodialysis patients.
- HCV infection contributes to hepatitis, liver cirrhosis, and primary liver cancer, and may cause liver disease in alcoholic patients.
Purpose of the Study:
- To establish the etiological role of HCV in various liver diseases.
- To explore the potential of recombinant interferon-alpha (IFN-alpha) in treating HCV-related liver disease.
- To emphasize the importance of preventing HCV infection through blood donor screening.
Main Methods:
- Epidemiological studies identifying HCV as the cause of NANB hepatitis.
- Serological testing for anti-HCV antibodies in patient populations.
- Review of existing data on HCV's contribution to liver pathology.
Main Results:
- HCV is identified as the primary cause of transfusion-associated and community-acquired NANB hepatitis in Japan.
- HCV infection is a significant factor in sporadic, acute, and chronic hepatitis, liver cirrhosis, and primary liver cancer.
- Anti-HCV antibodies were found in 20% of alcoholic patients with liver injury, suggesting HCV's role in these cases.
Conclusions:
- HCV is a major etiological agent for liver disease, including hepatitis, cirrhosis, and cancer.
- Recombinant IFN-alpha shows promise for treating acute and chronic HCV infections, preventing disease progression.
- Preventing HCV transmission via rigorous blood donor screening is essential to reduce post-transfusion hepatitis.
Abstract:
The HCV, a single stranded RNA virus belonging to the family of flavivirus, has been identified as the probable cause of the majority of cases of transfusion-associated NANB hepatitis and community-acquired NANB hepatitis in Japan. The hepatitis virus is present in a least 2% of the blood donor population and is extremely common in high risk groups, such as hemophiliacs and hemodialysis patients. The contribution of HCV infection to sporadic, acute and chronic hepatitis, liver cirrhosis and primary liver cancer has been established. Furthermore anti-HCV in 20% of alcoholic patients with liver injury suggest that HCV may be etiologically associated with liver disease previously attributed to other causes. Therapy of acute and chronic liver disease associated with HCV infection is likely to be undertaken with recombinant IFN alpha in the future to prevent the progression of the disease from acute hepatitis to chronic hepatitis, and from chronic hepatitis to liver cirrhosis or primary liver cancer. However the prevention of HCV infection will be the goal, in addition to screening of donor blood and exclusion to a large degree of positive units likely to decrease the incidence of post-transfusion hepatitis.